【摘要】：采用磷脂為基質(zhì)的新型原位凝膠作為鹽酸左布比卡因緩釋注射劑的載體。通過(guò)篩選磷脂類型、磷脂/乙醇比例、水分比例確定穩(wěn)定載藥的處方。制備的處方進(jìn)行了初步表征,符合原位凝膠的特點(diǎn)。進(jìn)行了比格犬藥代動(dòng)力學(xué)考察,上述處方的tmax滯后,t1/2延長(zhǎng),緩釋特征明顯。在豚鼠中進(jìn)行了藥效學(xué)評(píng)價(jià),上述處方局部麻醉效果顯著,相對(duì)于市售注射液,可維持長(zhǎng)達(dá)48~72 h的局麻效果。該新型原位凝膠具備良好的開發(fā)潛力。
[Abstract]:A novel in situ gel based on phospholipid was used as the carrier of levobupivacaine hydrochloric acid sustained release injection. The prescription of stable drug loading was determined by screening phospholipid type, phospholipid / ethanol ratio and moisture ratio. The prepared prescription was preliminarily characterized and was in accordance with the characteristics of in situ gel. The pharmacokinetics of Beagle dogs was investigated. The tmax of the above prescriptions was delayed, T1 鈮，

本文編號(hào)：2523558